Headline
The latest stories from AHA Today.
The three-part Beyond Birth podcast series explores how hospitals and health systems can support the social and emotional needs of pregnant people and new parents.
A new infographic by AHA explains how the Bipartisan Primary Care and Health Workforce Expansion Act’s (S. 2840) proposal to eliminate facility fees for telehealth services will impact access to care.
Starting Oct. 25, consumers can preview their 2024 health coverage options at the federally facilitated Health Insurance Marketplace.
The Department of Health and Human Services and the Cybersecurity and Infrastructure Security Agency Oct. 25 hosted a roundtable discussion with health care cybersecurity leaders, including the AHA, on the state of cybersecurity in the health care and public health sector.
AHA leaders are participating in the International Hospital Federation’s World Hospital Congress in Lisbon, Portugal.
The AHA’s Institute for Diversity and Health Equity Oct. 24 launched the Equity Transformation Partner program to connect AHA members with practitioners and service providers who can help them advance on their diversity, inclusion and health equity journey in alignment with AHA’s Health Equity…
The International Hospital Federation’s Geneva Sustainability Centre, in partnership with Deloitte, launched a Sustainability Accelerator Tool Oct. 24 to help hospital and health care leaders assess and track organizational efforts to reduce emissions and promote environmental stewardship.
The Centers for Disease Control and Prevention Oct. 23 released interim guidance for clinicians with limited access to the monoclonal antibody nirsevimab, recently approved to prevent respiratory syncytial virus in children aged 2 and under.
The share of health workers who reported feeling threatened or harassed by patients or others at work more than doubled between 2018 and 2022 to 13.4%, according to a new Centers for Disease Control and Prevention report based on national survey data.
The Food and Drug Administration recently extended to 30 months the shelf life for certain lots of Gohibic (vilobelimab), authorized for emergency use to treat COVID-19 in certain hospitalized adults.